Cancer Breakthrough Suppressed?

The recent human observational study from the Wellness Company examined a daily regimen of ivermectin combined with benazole in nearly 200 cancer patients. Results showed an 84% net benefit, with 48% of participants reporting tumor regression or complete disappearance and another 36% achieving disease stability. Only 15.6% experienced progression, and side effects were limited to gastrointestinal issues in roughly a quarter of the cohort. These outcomes suggest a potentially transformative, low‑cost therapeutic option that warrants further scientific scrutiny.

Repurposing established anti‑infective agents for oncology aligns with a growing movement to identify affordable alternatives to expensive chemotherapy. Dr. McCullough highlighted systemic disincentives within cancer centers, where high‑margin treatments generate greater revenue than inexpensive generics. This financial bias can delay the adoption of promising, cost‑effective therapies. By calling on the National Institutes of Health and the National Cancer Institute to launch large‑scale, double‑blind randomized trials, the discussion underscores the need for rigorous evidence to overcome regulatory hesitancy and to validate these early findings.

For patients eager to explore this option now, the Wellness Company offers direct enrollment through twc.health, using promo code VOICE for a discount. The platform provides the medication, monitors outcomes, and coordinates with patients’ oncologists to ensure safety. As the study expands to 12‑, 18‑, and 24‑month follow‑ups, real‑world data will further clarify efficacy and inform future clinical guidelines. This proactive patient‑centered approach could accelerate access to innovative cancer care while prompting the broader medical community to reconsider low‑cost drug repurposing strategies.